LAG3 and glioblastoma: The results indicated that the expression of CD274, CTLA4, PDCD1, and LAG3 in the samples of the high-risk group was significantly higher than that of the low-risk group, suggesting that the high expression of relevant genes might be one of the reasons that affected GBM treatment efficacy (Supplementary Figure S6F–I).